Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study

Table 2 Changes in LDLC and CVD risk from study entry to last follow up in 72 patients taking Alirocumab or Evolocumab

		Alirocumab 75 mg (n = 25) Follow up length median 24 weeks			Alirocumab 150 mg (n = 15) Follow up length median 26 weeks			Evolocumab 140 mg (n = 32) Follow up length median 24 weeks
Variable measured		percentile			percentile			percentile
Variable measured		25^th	50^th	75^th	25^th	50^th	75^th	25^th	50^th	75^th
LDLC	Entry (mg/dl)	100	117	143	133	175	214	143	165	211
	Follow up (mg/dl)	47	62	84	49	57	86	46	69	109
	Absolute change (mg/dl)	−35	−67	−85	−89	−104	−141	−65	−89	−131
	P (paired Wilcoxon)	p <.0001			p <.0001			p <.0001
	Percent change (%)	−27	−54	−63	−56	−63	−72	−40	−63	−71
	P (Wilcoxon)	p <.0001			p <.0001			p <.0001
CVD risk for next 10 years With AHA calculator	Entry (%)	3.9	6.2	18.0	5.4	9.3	20.4	4.3	11.5	18.6
	Follow up (%)	3.3	6.2	10.1	2.3	7.0	15.1	2.9	6.7	20.2
	Absolute change	−0.2	−1.6	−5.4	−0.7	−3.3	−6.0	−0.6	−2.4	−5.7
	P (paired Wilcoxon)	p = .0001			p = .0043			p = <.0001
	Percent change	−1.9	−22.2	−40.7	−22.2	−31.3	−39.0	−9.1	−28.7	−52.3
	P (Wilcoxon)	p = .0002			p = .0015			p <.0001
CVD risk for next 10 years With NIH calculator	Entry (%)	6.8	11.2	19.8	10.6	17.2	25.7	9.6	17.4	26.4
	Follow up (%)	4.3	7.4	11.7	5.1	6.5	12.3	5.3	8.0	12.0
	Absolute change	−1.4	−4.2	−10.5	−4.4	−9.1	−16.2	−3.0	−7.1	−14.7
	P (paired Wilcoxon)	p <.0001			p = .0001			P <.0001
	Percent change	−21.4	−43.7	−53.5	−41.6	−49.8	−61.4	−27.9	−55.5	−66.2
	P (Wilcoxon)	p <.0001			p = .0001			p <.0001

ISSN: 1476-511X